Sensei Biotherapeutics Inc
F:407
Sensei Biotherapeutics Inc
F:407
Price:
5.2
EUR
Market Closed
Market Cap:
€138.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Sensei Biotherapeutics Inc
F:407
|
US |
|
Afterpay Ltd
ASX:APT
|
AU |
|
M
|
Midland Holdings Ltd
HKEX:1200
|
HK |
|
E
|
Element Lifestyle Retirement Inc
XTSX:ELM
|
CA |
|
I
|
ICON PLC
SWB:IJF
|
IE |
|
P
|
Paradox Interactive AB (publ)
STO:PDX
|
SE |
|
BCE Inc
TSX:BCE
|
CA |
|
Sarcos Technology and Robotics Corp
NASDAQ:PDYN
|
US |
|
W
|
World Fuel Services Corp
F:WFK
|
US |
|
Anhui Sierte Fertilizer Industry Ltd Co
SZSE:002538
|
CN |
|
E
|
EROAD Ltd
ASX:ERD
|
NZ |
|
Fenix Resources Ltd
ASX:FEX
|
AU |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
PR |
|
8
|
888 Holdings PLC
OTC:EIHDF
|
GI |
|
C
|
Cartrade Tech Ltd
NSE:CARTRADE
|
IN |
|
Kaluzhskaya Sbytovaya Kompaniya PAO
MOEX:KLSB
|
RU |
|
C
|
Czerwona Torebka SA
WSE:CZT
|
PL |
|
A
|
Argent Minerals Ltd
XBER:AR8
|
AU |
|
N
|
NTT Data Group Corp
DUS:NT5
|
JP |
|
Doumob
HKEX:1917
|
CN |
|
B
|
Belluscura PLC
LSE:BELL
|
UK |
|
F
|
Fusion Micro Finance Ltd
NSE:FUSION
|
IN |
Income Statement
Earnings Waterfall
Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc
Income Statement
Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc
Currency: USD
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||
| Interest Expense |
3
|
2
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||
| Operating Expenses |
(17)
|
(19)
|
(23)
|
(28)
|
(33)
|
(37)
|
(41)
|
(42)
|
(47)
|
(50)
|
(49)
|
(48)
|
(42)
|
(37)
|
(35)
|
(32)
|
(32)
|
(32)
|
(31)
|
(29)
|
(26)
|
(22)
|
|
| Selling, General & Administrative |
(6)
|
(8)
|
(10)
|
(13)
|
(15)
|
(16)
|
(16)
|
(17)
|
(18)
|
(20)
|
(21)
|
(22)
|
(21)
|
(19)
|
(17)
|
(15)
|
(14)
|
(13)
|
(13)
|
(12)
|
(11)
|
(11)
|
|
| Research & Development |
(11)
|
(11)
|
(12)
|
(15)
|
(18)
|
(22)
|
(26)
|
(26)
|
(29)
|
(30)
|
(28)
|
(27)
|
(21)
|
(18)
|
(18)
|
(18)
|
(19)
|
(19)
|
(17)
|
(15)
|
(13)
|
(11)
|
|
| Operating Income |
(17)
N/A
|
(19)
-10%
|
(23)
-25%
|
(28)
-21%
|
(33)
-18%
|
(37)
-13%
|
(41)
-11%
|
(42)
-2%
|
(47)
-10%
|
(50)
-8%
|
(49)
+3%
|
(48)
+1%
|
(42)
+13%
|
(37)
+12%
|
(35)
+6%
|
(32)
+7%
|
(32)
0%
|
(32)
+3%
|
(31)
+2%
|
(29)
+8%
|
(26)
+10%
|
(22)
+13%
|
|
| Pre-Tax Income | |||||||||||||||||||||||
| Interest Income Expense |
(4)
|
(1)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
3
|
4
|
3
|
3
|
3
|
3
|
2
|
2
|
2
|
1
|
1
|
|
| Non-Reccuring Items |
(1)
|
(1)
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(22)
N/A
|
(20)
+7%
|
(23)
-16%
|
(28)
-21%
|
(33)
-15%
|
(37)
-13%
|
(41)
-12%
|
(42)
-2%
|
(46)
-9%
|
(49)
-6%
|
(46)
+5%
|
(45)
+2%
|
(39)
+14%
|
(34)
+12%
|
(32)
+6%
|
(30)
+7%
|
(30)
0%
|
(30)
-1%
|
(29)
+4%
|
(27)
+8%
|
(24)
+10%
|
(21)
+13%
|
|
| Net Income | |||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(22)
|
(20)
|
(23)
|
(28)
|
(33)
|
(37)
|
(41)
|
(42)
|
(46)
|
(49)
|
(46)
|
(45)
|
(39)
|
(34)
|
(32)
|
(30)
|
(30)
|
(30)
|
(29)
|
(27)
|
(24)
|
(21)
|
|
| Net Income (Common) |
(23)
N/A
|
(20)
+11%
|
(23)
-16%
|
(28)
-21%
|
(33)
-15%
|
(37)
-13%
|
(41)
-12%
|
(42)
-2%
|
(46)
-9%
|
(49)
-6%
|
(46)
+5%
|
(45)
+2%
|
(39)
+14%
|
(34)
+12%
|
(32)
+6%
|
(30)
+7%
|
(30)
0%
|
(30)
-1%
|
(29)
+4%
|
(27)
+8%
|
(24)
+10%
|
(21)
+13%
|
|
| EPS (Diluted) |
-15.38
N/A
|
-13.66
+11%
|
-24.73
-81%
|
-18.46
+25%
|
-21.28
-15%
|
-26.55
-25%
|
-26.91
-1%
|
-27.36
-2%
|
-29.77
-9%
|
-31.65
-6%
|
-30.04
+5%
|
-29.64
+1%
|
-30.5
-3%
|
-24.4
+20%
|
-25.48
-4%
|
-23.63
+7%
|
-23.7
0%
|
-24.01
-1%
|
-23.04
+4%
|
-21.27
+8%
|
-19.13
+10%
|
-16.72
+13%
|
|
Switch to:
Switch to:
See Also
Discover More
